research centers


Search results: Found 4

Listing 1 - 4 of 4
Sort by

Article
P53 Expression in Endometrial Hyperplasia and Endometrial Carcinoma
التعبير P53 في فرط تنسج بطانة الرحم وسرطان بطانة الرحم

Authors: Rivan Hermiz Isaac --- Nadya Y. Ahmed
Journal: Zanco Journal of Medical Sciences مجلة زانكو للعلوم الطبية ISSN: 19955588/19955596 Year: 2010 Volume: 14 Issue: 2 Pages: 28-34
Publisher: Hawler Medical Univeristy جامعة هولير الطبية

Loading...
Loading...
Abstract

Background and Objectives: Mutations of the P53 tumor suppressor gene and altera-tions in its protein expression often occur in a variety of human malignant tumors, including endometrial carcinoma, but the practical implications of this phenomenon are yet to be fully exploited. This study was designed to evaluate P53 protein expression in normal, hyper-plastic and malignant endometrium by immunohistochemical study and to correlate P53 expression in endometrial carcinoma with other clinic-pathological prognostic parameters (age, histologic type, tumor grade, cervical & myometrial invasion, and tumor stage).Methods: The studied samples included 100 formalin fixed, paraffin embedded endo-metrial tissue specimens which were divided to the following diagnostic categories: - Pro-liferative endometrium (n=10); secretory endometrium (n=10); simple hyperplasia (n=10); complex hyperplasia without atypia (n=20); atypical complex hyperplasia (n=10) and endo-metrial carcinoma (n=40).Results: None of the normal endometrium, simple hyperplasia and complex hyperplasia without atypia showed P53 immunostaining, while 20% of atypical complex hyperplasia and 32.5% of endometrial carcinoma showed immunoreactivity for P53. In endometrial car-cinoma, significant correlation was observed between P53 expression and age at diagno-sis, histological grade,FIGO stage, myometrial invasion & cervical invasion ; but not with the histological type .Conclusions: The results indicated the validity & simplicity of the application of immuno-histochemistry in determining the status of P53 overexpresion which is strongly associated with endometrial carcinoma aggressiveness and high malignant potential.


Article
Immunohistochemical detection of estrogenreceptor ل in endometrial carcinoma

Authors: Wahda MT Al- Nuaimy وحدة محمد طيب النعيمي --- Abeer H. Ahmed عبير أحمد
Journal: Annals of the College of Medicine Mosul مجلة طب الموصل ISSN: 00271446 23096217 Year: 2010 Volume: 36 Issue: 1&2 Pages: 130-137
Publisher: Mosul University جامعة الموصل

Loading...
Loading...
Abstract

Objective: To evaluate the immunohistochemical expression of estrogen receptor alpha (ERα) in patients with endometrial carcinoma in Mosul city and to correlate it with various clinical and pathological parameters.Methods: Sixty cases of endometrial carcinoma were collected from Al-Batool Teaching Hospital, Al-Khansaa Teaching Hospital, private laboratories during a period extending from January 2007 – to January 2009. The tumors were typed according to the World Health Organization classification system and graded according to FIGO grading system. The expression of ERα was evaluated immunohistochemically; the findings were correlated with the age of the patients, type and grade of the tumor and the extent of myometrial invasion. ERα status was assessed immunohistochemically on formalin fixed paraffin embedded (FFPE) tissue of tumor, using monoclonal mouse antibody (IgG1) clone ID5. A semi-quantitative score was used to record the results of ERα staining according to the system established by Carcangiu et al.Results: The patients age ranged from 31 to 70 years (mean = 56.5). Histopathological typing revealed that 55 cases (91.7%) were endometrioid carcinoma which included [46 cases (83.6%) typical, 5 cases (9.1%) villoglandular, 3 cases (5.5%) adenosquamous and 1 case (1.8%) secretory type] and 5 cases (8.3%) were non-endometrioid carcinoma [2 cases (40%) papillary serous and 3 cases (60%) with clear cell type]. The overall expression of ERα in endometrial carcinoma is 60%, ERα was failed to show a statistically significant correlation with the age (P value = 0.9). A statistically significant association was found between ERα expression and types of endometrial carcinoma (P value = 0.004). In endometrioid carcinoma, the ERα expression was detected in 65.5%, whereas non-endometrioid carcinoma failed to demonstrate positivity (0.0%). There was a significant inverse relation between ERα expression and the grade of the tumor (P value = 0.001). There was a significant inverse relation between ERα expression and the extent of myometrial invasion (P value = 0.004). Conclusions: ER α is expressed in 60% of endometrial carcinoma in Mosul city. ERα is significantly expressed in endometrioid carcinoma, while it is negative in non-endometrioid carcinoma. ERα expression is inversely correlated with the grade of endometriod carcinoma and the extent of myometrial invasion.Keywords: ERα , endometrial carcinoma, endometrioid carcinoma, non-endometrioid carcinoma.

الهــدف: تهدف هذه الدراسة إلى تقيم حالات مستقبلات الاستروجين ألفا لسرطان بطانة الرحم في مدينة الموصل ولإيجاد أي علاقة بينها وبين مختلف الصفات المرضية للورم ومقارنة النتائج مع نتائج دراسات أخرى.الحالات والطرق: لقد تم إجراء دراسة تضمنت ستين حالة سرطان بطانة الرحم ولقد تم تجميع الحالات من مستشفى البتول التعليمي، مستشفى الخنساء ومن بعض المختبرات الخاصة خلال فترة امتدت بين شهري كانون الثاني ٢٠٠۷ وكانون الثاني ٢٠٠٩. ولقد تم تصنيف سرطان بطانة الرحم وفقا لتصنيف منظمة الصحة العالمية ولقد تم تقسيم درجة التمايز الخلوي وفقا لمنظمة الدولية الفدرالية للنسائية والتوليد. تم التحري على مستقبلات الاستروجين ألفا بطريقة الكيمياء النسيجي المناعي باستخدام المضادات أحادية النسل (المضاد أحادي النسل نوع نوع١دي٥) ونظام اظهار نوع المعلم تي ام جي/1 أي دي، فأر(احمر دائم). وتم تحليل النتائج بطريقة شبه كمية، وإيجاد العلاقة مع عمر المريض، نوع النسيج الخلوي للورم، درجة التمايز الخلوي و نسبة الانتشار إلى العضلة الرحمية طبقا للنظام المستخدم من قبل كاركينجو.النتائج: لقد تراوحت أعمار المرضى بين واحد ثلاثين وسبعين سنة وكان المعدل ٥, ٥٦ سنة. حيث وجد فشل في العلاقة بين مستقبلات استر وجين ألفا وبين العمر (٠٫٩= P). لقد وجدت مستقبلات استروجين ألفا في ٦٠% من سرطان بطانة الرحم. ولقد اظهر الفحص النسيجي (نوع النسيج الخلوي للورم) وجود ٥٥ حالة (٩١٫۷ %) سرطان من بطأني الرحم ألغدي، كما وجدت علاقة بين مستقبلات استروجين ألفا وبين نوع النسيج الخلوي للورم (٠٫٠٠٤ p=). تضمنت درجة التمايز الخلوي ٣١ حالة (٤,٥٦ %) من نوع سرطان جيد التمايز الخلوي ١٨ حالة (٣٢٫۷%) من نوع سرطان متوسط التمايز الخلوي و٦ حالات (١٠٫٩%) من نوع سرطان غير متمايز خلويا . حيث وجد علاقة عكسية بين مستقبلات استروجين ألفا وبين درجة التمايز الخلوي (٠٫٠٠١p=). نسبة الانتشار إلى العضلة الرحمية قسمت إلى ثلاث أقسام حسب مستوى الانتشار. حيث ظهرت ٥ حالات عدم وجود انتشار للورم بالعضلية الرحمية و٢٠ حالة وجود انتشار للورم بالعضلية الرحمية اقل أو يساوي (٥٠%) من التثخن الكلي للعضلة الرحمية و٢٠ حالة وجود انتشار للورم بالعضلية الرحمية أكثر من (٥٠%) من التثخن الكلي للعضلة الرحمية. حيث وجد علاقة عكسية بين مستقبلات استر وجين ألفا وبين نسبة الانتشار إلى العضلة الرحمية (٠٫٠٠٤P=). الاستنتاجات:-وجدت نسبة مستقبلات استر وجين ألفا في (٦٠%) من سرطان بطانة الرحم في مدينة الموصل.-وجود علاقة بين مستقبلات استروجين ألفا وبين سرطان بطاني الرحم الغدي بالمقارنة مع الورم اللابطاني لسرطان بطانة الرحم.-وجود علاقة عكسية بين مستقبلات استروجين ألفا وبين كل من درجة التمايز الخلوي ونسبة الانتشار إلى العضلة الرحمية.


Article
Comparison between Transvaginal Sonography and Magnetic Resonance Imaging Study Findings in Patient with Endometrial Carcinoma

Authors: Fowz Adnan Yaser --- Ausama Ayaad Al-Bayati
Journal: Medical Journal of Babylon مجلة بابل الطبية ISSN: 1812156X 23126760 Year: 2017 Volume: 14 Issue: 4 Pages: 640-648
Publisher: Babylon University جامعة بابل

Loading...
Loading...
Abstract

The main objective of this study is to compare between the findings that obtained from both TVS and MRI study in diagnosis of endometrial carcinoma and differentiate it from other endometrial pathology and to assess the accuracy of both techniques in evaluation and detection of myometrium invasion. This prospective study was done in AL- Hilla Teaching Hospital from August 2016 to August 2017 on (22) patients, their ages were from 46-79 years old, (18) of them are postmenopausal and (4) patients are premenopausal, all of them were suffering from recurrent dysfunctional vaginal bleeding. Patients are examined by both TVS and MRI study with contrast endometrial carcinoma is suggested and histopathology insisted the diagnosis, comparison between two techniques is reported.By TVS (7) of the patients have bulky size uterus with different endometrial masses size and texture, other (15) patients have just irregular increase in endometrial thickness. Myometrial invasion which is the most important prognostic factor was as follows: (2) patients have no distinct invasion, (7) patients have less than 1/3 myometrial invasion, (9) patients have more than 2/3 of myometrial invasion; in comparison with enhanced MRI study; findings were that (13) of patients have well defined different sizes and intensity masses, (9) patients have irregular increase in endometrial thickness with different degree of myometrial invasion, myometrial invasion was as follows: (9) patients with less than 1/3 of myometrial invasion, (9) patients with more than 2/3 of myometrial invasion, (2) patients the invasion reaching to serosa and involving the cervix. The conclusions from this imaging assumes increasing importance in the management of patients with endometrial carcinoma in recent years. Transvaginal sonography that performed by expert specialist can be consider a feasible, economic imaging modality with diagnostic accuracy comparable to that of MRI in preoperative local staging of endometrial cancer. Dynamic contrast enhanced MRI study is more accurate in diagnosis and evaluation of endometrial carcinoma and assessment of myometrial invasion. Early disease detection and accurate staging provide optimal management and minimize mortality and morbidity.


Article
1. Editorial :GENOMIC BIOMARKERS IN ENDOMETRIAL CARCINOMA

Author: Noora M. Kareem نورا مصطفى كريم
Journal: IRAQI JOURNAL OF MEDICAL SCIENCES المجلة العراقية للعلوم الطبية ISSN: P16816579,E22244719 Year: 2019 Volume: 17 Issue: 2 Pages: 100-102
Publisher: Al-Nahrain University جامعة النهرين

Loading...
Loading...
Abstract

Endometrial carcinoma is the second most common gynecological cancer in developing countries after cervical carcinoma and its incidence is increasing due to the rise in the rate of obesity. Diagnosis depend on invasive test (biopsy) with no routine screening investigation available for either general population or high-risk group, there are several types of biomarkers that can be used for diagnosis, prognosis and management but none are available for routine clinical practice. Following the discovery of the new gene-based classifications of endometrial cancer, the use of these gene-based biomarkers will be the cornerstone in the early diagnosis and management for endometrial carcinoma patients in the coming years.Keywords:Endometrial carcinoma, screening, PTEN, miRNA, P53, circulating tumor DNA, genomic classificationCitation:Kareem NM. Genomic biomarkers in endometrial carcinoma. Iraqi JMS. 2019; 17(2): 100-102. doi: 10.22578/IJMS.17.2.1

Listing 1 - 4 of 4
Sort by
Narrow your search

Resource type

article (4)


Language

English (2)

Arabic and English (1)


Year
From To Submit

2019 (1)

2017 (1)

2010 (2)